Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot cuts dangerous fat levels in half

NCT ID NCT04720534

Disease control Sponsor: Arrowhead Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called ARO-APOC3 in 229 adults with severely high triglycerides (a type of blood fat). Participants received two injections of the drug or a placebo. The goal was to see if the drug could safely lower triglyceride levels. Results showed significant reductions, offering a potential new option for managing this condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

229 people

The number who actually took part.

Started

May 2021

Finished

Aug 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Based on medical history, evidence of triglycerides (TG) ≥ 500 mg/dL and ≤ 4000 mg/dL at Screening * Fasting TG ≥ 500 mg/dL at Screening * Willing to follow diet counseling per Investigator judgment based on local standard of care * Women of childbearing potential must have a negative pregnancy test, cannot be breastfeeding, and must be willing to use contraception * Willing to provide written informed consent and to comply with study requirements Exclusion Criteria: * Active pancreatitis within 12 weeks prior to first dose * Any planned bariatric surgery or similar procedures to induce weight loss from consent to end of study * Acute coronary syndrome event within 24 weeks of first dose * Major surgery within 12 weeks of first dose * Planned coronary intervention (e.g., stent placement or heart bypass) or any non-cardiac major surgical procedure throughout the study * Uncontrolled hypertension * Human immunodeficiency virus (HIV) infection, seropositive for Hepatitis B (HBV), seropositive for Hepatitis C (HCV) * Uncontrolled hypothyroidism or hyperthyroidism * Hemorrhagic stroke within 24 weeks of first dose * Malignancy within the last 2 years prior to date of consent requiring systemic treatment (some exceptions apply) Note: additional inclusion/exclusion criteria may apply per protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Severe hypertriglyceridemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertriglyceridemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Severe hypertriglyceridemia

Contacts and locations

Locations

  • Research Site 10

    Miami, Florida, 33144, United States

  • Research Site 11

    Miami, Florida, 33155, United States

  • Research Site 12

    Miami Springs, Florida, 33166, United States

  • Research Site 14

    Port Orange, Florida, 32127, United States

  • Research Site 16

    Dunwoody, Georgia, 30338, United States

  • Research Site 17

    Arlington Heights, Illinois, 60005, United States

  • Research Site 18

    Lexington, Kentucky, 40503, United States

  • Research Site 2

    Beverly Hills, California, 90211, United States

  • Research Site 20

    Minneapolis, Minnesota, 55455, United States

  • Research Site 21

    Tupelo, Mississippi, 38801, United States

  • Research Site 22

    Kalispell, Montana, 59901, United States

  • Research Site 23

    Omaha, Nebraska, 68114, United States

  • Research Site 24

    Las Vegas, Nevada, 89121, United States

  • Research Site 25

    Long Island City, New York, 11106, United States

  • Research Site 26

    New Windsor, New York, 12553, United States

  • Research Site 27

    New York, New York, 10029, United States

  • Research Site 29

    Morehead City, North Carolina, 28557, United States

  • Research Site 30

    Fargo, North Dakota, 58104, United States

  • Research Site 31

    Dayton, Ohio, 45419, United States

  • Research Site 32

    Franklin, Ohio, 45005, United States

  • Research Site 33

    Maumee, Ohio, 43537, United States

  • Research Site 34

    Oklahoma City, Oklahoma, 73135, United States

  • Research Site 35

    Greenville, South Carolina, 29607, United States

  • Research Site 36

    Chattanooga, Tennessee, 37421, United States

  • Research Site 38

    Houston, Texas, 77030, United States

  • Research Site 39

    Houston, Texas, 77099, United States

  • Research Site 4

    Palm Springs, California, 92292, United States

  • Research Site 40

    San Antonio, Texas, 78249, United States

  • Research Site 41

    Manassas, Virginia, 20110, United States

  • Research Site 42

    Camperdown, New South Wales, 2050, Australia

  • Research Site 43

    Perth, Nedlands, 6009, Australia

  • Research Site 44

    Brisbane, Queensland, 4064, Australia

  • Research Site 45

    Sippy Downs, Queensland, 4556, Australia

  • Research Site 46

    Adelaide, South Australia, 5000, Australia

  • Research Site 47

    Clayton, Victoria, 3168, Australia

  • Research Site 49

    Concord, Ontario, L4K 4M2, Canada

  • Research Site 5

    Boca Raton, Florida, 33434, United States

  • Research Site 50

    London, Ontario, N6A 5A5, Canada

  • Research Site 51

    Toronto, Ontario, M4G 3E8, Canada

  • Research Site 52

    Chicoutimi, Quebec, G7H5H6, Canada

  • Research Site 53

    Greenfield, Quebec, J4V2G8, Canada

  • Research Site 54

    Montreal, Quebec, H2W2T2, Canada

  • Research Site 55

    Aachen, 52074, Germany

  • Research Site 56

    Leipzig, 0 4103, Germany

  • Research Site 57

    Baja, 6500, Hungary

  • Research Site 58

    Baja, 6500, Hungary

  • Research Site 59

    Balatonföldvár, H-8230, Hungary

  • Research Site 6

    Fort Lauderdale, Florida, 33308, United States

  • Research Site 60

    Békéscsaba, 5600, Hungary

  • Research Site 61

    Debrecen, 4032, Hungary

  • Research Site 62

    Gyöngyös, 3200, Hungary

  • Research Site 63

    Komárom, 2921, Hungary

  • Research Site 64

    Nyíregyháza, 4405, Hungary

  • Research Site 65

    Nyíregyháza, 4400, Hungary

  • Research Site 66

    Amsterdam, 1105 AZ, Netherlands

  • Research Site 67

    Dordrecht, 3318 AT, Netherlands

  • Research Site 68

    Sneek, 08601, Netherlands

  • Research Site 69

    Christchurch, 8011, New Zealand

  • Research Site 70

    Hamilton, 3200, New Zealand

  • Research Site 71

    Papatoetoe, 2025, New Zealand

  • Research Site 72

    Rotorua, 3010, New Zealand

  • Research Site 73

    Grafton, Auckland, 1010, New Zealand

  • Research Site 74

    Bydgoszcz, 85-605, Poland

  • Research Site 75

    Elblag, 82-300, Poland

  • Research Site 76

    Gdynia, 81-157, Poland

  • Research Site 77

    Łęczyca, 99-100, Poland

  • Research Site 78

    Oświęcim, 32-600, Poland

  • Research Site 79

    Poznan, 61-655, Poland

  • Research Site 8

    Miami, Florida, 33173, United States

  • Research Site 80

    Puławy, 24-100, Poland

  • Research Site 81

    Rzeszów, 35-055, Poland

  • Research Site 82

    Wołomin, 05-200, Poland

  • Research Site 83

    Lodz, 94-048, Poland

  • Research Site 9

    Miami, Florida, 33144, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.